Latent Mycobacterium tuberculosis Infection and Laboratory Test Methods (Online CE Course)

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1 hour(s) Approved through 1/31/2025

Florida Board of Clinical Laboratory Personnel Credit Hours - General (Microbiology/Mycology/Parasitology): 1 hour(s) Approved through 1/31/2025

Objectives

• Describe the difference between active tuberculosis [TB] disease and latent tuberculosis infection [LTBI], list terms and abbreviations.
• Describe the etiology (cause of disease) and pathogenesis (manner of development) of TB disease and LTBI.
• Review the epidemiology (occurrence and distribution) of TB disease and LTBI in the United States (US) and globally.
• Targeted testing: Describe who should be tested for TB infection (risk factors).
• Describe recommended TB test methods, interpretations, and limitations (TB skin test [TST] versus laboratory TB blood tests to include interferon-gamma release assays [IGRA]).
• Describe recommended treatment and management regimens for patients with LTBI (to include laboratory monitoring).

Customer Ratings

(based on 344 customer ratings)

Course Outline

• Introduction
• Introduction
• Historical Background
• What is the Difference Between LTBI and Active TB?
• Terminology
• List of Terms and Abbreviations
• Which of the following statements is correct regarding LTBI?
• Select the statement which best corresponds to the abbreviation: IGRA.
• Etiology and Pathogenesis of TB Disease and LTBI
• Etiology: What is the Cause of Tuberculosis?
• Pathogenesis: What is the Process by which Tuberculosis (TB) Develops?
• Pathogenesis: What is the Process by which Latent Tuberculosis Infection (LTBI) Develops?
• Pathogenesis: Risk of Activation from LTBI to Active TB Disease
• Individuals with latent tuberculosis infection (LTBI) experience what immune response?
• Expected laboratory findings in a case of latent tuberculosis infection (LTBI) might be:
• The risk of activation from LTBI to active TB disease is approximately 17-20% over an individual's lifetime.
• Epidemiology
• Epidemiology: What is it? Why is it important?
• Epidemiology: TB and LTBI in the United States
• Epidemiology: TB and LTBI in the World
• Epidemiology: Special Consideration - The HIV-infected
• At present, the prevalence of LTBI (people living with TB infection) in the United States is estimated to be as high as:
• It is estimated that half of the world's population has latent TB infection (LTBI).
• Targeted Testing: Who Should be Tested?
• Targeted Testing: Who Should be Tested for TB Infection?
• Targeted Testing: Who Should be Tested for TB Infection? (continued...)
• Special Consideration: Those Vaccinated with Bacille Calmette-Guerin (BCG) Vaccine
• Persons at high risk for TB infection fall into which two broad categories?
• Which statement best reflects people at high risk for TB infection or TB disease after infection? (Those targeted for testing?)
• TB Test Methods
• TB Test Methods
• Additional Considerations
• The Role of the Laboratorian: Troubleshooting Unusual Results
• Tuberculin Skin Test (TST)
• Tuberculin Skin Test (TST): Description
• Tuberculin Skin Test (TST): Procedure
• Tuberculin Skin Test (TST): Test Frequency and Interpretation of Results
• Tuberculin Skin Test (TST): Limitations
• A false-positive TST may occur when:
• Which of the following statements is correct when describing the TST procedure?
• Interferon Gamma Release Assay (IGRA)
• Interferon Gamma Release Assay (IGRA): Description
• Interferon Gamma Release Assay (IGRA): Procedure
• Interferon Gamma Release Assay (IGRA): Interpretation of Results
• Interferon Gamma Release Assay (IGRA): Limitations
• Which of the following is true of current IGRA test methods for determining TB status?
• The interferon gamma release assay (IGRA):
• Treatment and Management
• Recommended Treatment Regimens for LTBI
• Recommended Treatment Regimens for LTBI (continued...)
• Recommended Patient Management Regimen for LTBI
• In Summary
• Duration of drug treatment for LTBI may be as short as three months (12 total doses) and includes:
• Patient management for individuals on drug treatment for LTBI include:
• References
• References
• Image References
• Image References

Additional Information